Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A cost-effectiveness analysis based on a multicenter clinical trial

被引:21
作者
Jasmer, RM
Snyder, DC
Saukkonen, JJ
Hopewell, PC
Bernardo, J
King, MD
Kawamura, LM
Daley, CL
机构
[1] San Francisco Gen Hosp, Med Ctr, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Francis J Curry Natl TB Ctr, San Francisco, CA USA
[4] Boston Univ, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02118 USA
[5] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA
[6] Grady Mem Hosp, Dept Epidemiol, Atlanta, GA USA
关键词
D O I
10.1086/380966
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two months of treatment with rifampin-pyrazinamide (RZ) and 9 months of treatment with isoniazid are both recommended for treatment of latent tuberculosis infection in adults without human immunodeficiency virus infection, but the relative cost-effectiveness of these 2 treatments is unknown. We used a Markov model to conduct a cost-effectiveness analysis to assess the impact on life expectancy and costs based on the results of a recent clinical trial that compared the rates of adverse events and completion of the 2 treatment regimens. Compared with no treatment, both regimens increased life expectancy by 1.2 years, but RZ cost $273 more per patient. Sensitivity analyses showed that, assuming equal efficacy between the 2 regimens, there was no threshold completion rate for RZ at which the 2 treatments would be of equal net cost. Under most circumstances, treatment of latent tuberculosis infection with isoniazid is cost-saving than treatment with RZ.
引用
收藏
页码:363 / 369
页数:7
相关论文
共 20 条
[1]  
ANDERSON RN, 2001, NATL VITAL STAT REPO, V48
[2]  
[Anonymous], 2001, MMWR MORB MORTAL WKL, V50, P733
[3]  
[Anonymous], AM J RESP CRIT CARE
[4]   A CONVENIENT APPROXIMATION OF LIFE EXPECTANCY (THE DEALE) .1. VALIDATION OF THE METHOD [J].
BECK, JR ;
KASSIRER, JP ;
PAUKER, SG .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) :883-888
[5]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[6]  
FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28
[7]   Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons - An international randomized trial [J].
Gordin, F ;
Chaisson, RE ;
Matts, JP ;
Miller, C ;
Garcia, MD ;
Hafner, R ;
Valdespino, JL ;
Coberly, J ;
Schechter, M ;
Klukowicz, AJ ;
Barry, MA ;
O'Brien, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (11) :1445-1450
[8]   Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection [J].
Halsey, NA ;
Coberly, JS ;
Desormeaux, J ;
Losikoff, P ;
Atkinson, J ;
Moulton, LH ;
Contave, M ;
Johnson, M ;
Davis, H ;
Geiter, L ;
Johnson, E ;
Huebner, R ;
Boulos, R ;
Chaisson, RE .
LANCET, 1998, 351 (9105) :786-792
[9]   Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial [J].
Jasmer, RM ;
Saukkonen, JJ ;
Blumberg, HM ;
Daley, CL ;
Bernardo, J ;
Vittinghoff, E ;
King, MD ;
Kawamura, LM ;
Hopewell, PC .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (08) :640-647
[10]  
KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991